Cantor Fitzgerald Weighs in on Scholar Rock FY2025 Earnings

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for Scholar Rock down to ($3.41), from a previous estimate of ($3.14).
• Scholar Rock's latest quarterly report showed an EPS of ($0.98), missing consensus estimates by ($0.32).
• The stock has received multiple ratings and price targets from analysts, including a "strong-buy" from Raymond James with a price objective of $53.00.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for Scholar Rock in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will earn ($3.41) per share for the year, down from their prior estimate of ($3.14). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Scholar Rock's FY2026 earnings at ($2.93) EPS.

Several other research firms also recently commented on SRRK. Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a research note on Tuesday, June 3rd. Wedbush restated an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a report on Wednesday, June 18th. Raymond James Financial set a $53.00 price target on Scholar Rock and gave the stock a "strong-buy" rating in a research report on Wednesday, July 30th. Finally, BMO Capital Markets reduced their target price on Scholar Rock from $57.00 to $45.00 and set an "outperform" rating on the stock in a research report on Thursday, August 7th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Scholar Rock currently has an average rating of "Buy" and an average target price of $45.14.

Scholar Rock Stock Performance

SRRK stock traded up $0.46 during trading on Monday, reaching $32.44. The stock had a trading volume of 364,831 shares, compared to its average volume of 1,222,482. Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The stock's 50 day moving average is $35.83 and its two-hundred day moving average is $34.25. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.12 billion, a PE ratio of -11.12 and a beta of 0.48.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.32). During the same quarter in the prior year, the company earned ($0.60) earnings per share.

Institutional Investors Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC boosted its position in shares of Scholar Rock by 152.8% during the first quarter. CWM LLC now owns 996 shares of the company's stock worth $32,000 after buying an additional 602 shares during the period. Federated Hermes Inc. purchased a new position in shares of Scholar Rock during the first quarter worth $71,000. GF Fund Management CO. LTD. boosted its position in shares of Scholar Rock by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock worth $77,000 after buying an additional 430 shares during the period. Strs Ohio purchased a new position in shares of Scholar Rock during the first quarter worth $77,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Scholar Rock during the second quarter worth $94,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 24,066 shares of the stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $34.44, for a total transaction of $828,833.04. Following the completion of the transaction, the insider owned 115,495 shares of the company's stock, valued at $3,977,647.80. This represents a 17.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey S. Flier sold 11,136 shares of the stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $40.02, for a total value of $445,662.72. Following the transaction, the director directly owned 24,070 shares of the company's stock, valued at $963,281.40. The trade was a 31.63% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 93,654 shares of company stock valued at $3,101,811. 13.30% of the stock is owned by insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.